Acta Haematologica最新文献

{"title":"Reconsidering Asparaginase in Leukemia Therapy.","authors":"Maria Frost, Vivek Subbiah, Branko Cuglievan, Miriam B Garcia","doi":"10.1159/000551486","DOIUrl":"https://doi.org/10.1159/000551486","url":null,"abstract":"","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-5"},"PeriodicalIF":1.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia.","authors":"Xinxin Li, Liangliang Wu, Yumiao Li, Wenjian Mo, Xiaowei Chen, Ming Zhou, Ruiqing Zhou, Shilin Xu, Shiyi Pan, Caixia Wang, Shunqing Wang, Yuping Zhang","doi":"10.1159/000551296","DOIUrl":"https://doi.org/10.1159/000551296","url":null,"abstract":"<p><p>The prognosis and management of pregnancy-associated aplastic anemia (PAA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. This study evaluated the safety and feasibility of allo-HSCT in 18 patients with PAA who were treated between January 2013 and November 2023. The donor types included 8 matched sibling donors, 1 matched unrelated donor, 3 mismatched unrelated donors, and 6 haploidentical donors. Median neutrophil engraftment occurred at 11.5 days (range: 6-15), and platelet engraftment occurred at 11.5 days (range: 7-28). The cumulative incidence (CI) of both neutrophil and platelet engraftments was 100%. The CI rates were 22.96%±10.10% for grade II acute graft-versus-host disease (aGVHD) and 12.61%±8.37% for chronic GVHD (cGVHD). No cases of grade III-IV aGVHD, extensive cGVHD, or relapse were observed. The CI of transplantation-related mortality was 19.87%±10.49%. Among the 15 surviving patients, the median follow-up was 1,409 days (range: 228-3,666). The overall survival (OS) and relapse/rejection-free (GRFS) rates were both 80.14%±10.49%. These findings suggest that allo-HSCT is a viable and effective treatment option for PAA.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-23"},"PeriodicalIF":1.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BEAC Induction Regimen and Prior Thoracic Radiotherapy Increases the Risk of ASCT-Associated Pneumonitis.","authors":"Elina Kaprio, Anna Jokimäki, Hanne Kuitunen, Joel Kontiainen, Tuomas Selander, Taina Turpeenniemi-Hujanen, Outi Kuittinen","doi":"10.1159/000551311","DOIUrl":"10.1159/000551311","url":null,"abstract":"<p><strong>Introduction: </strong>High-dose chemotherapy (HDT) followed by autologous stem cell transplant (ASCT) has been standard of care in the treatment of relapsed and refractory lymphoma. Some severe toxicities are associated with this treatment modality. Pulmonary toxicity is one of these significant adverse effects and a potential cause of treatment-related mortality.</p><p><strong>Methods: </strong>In this retrospective study, we report the incidence, risk factors, and outcome of treatment-induced pneumonitis in 286 lymphoma patients receiving HDT followed by ASCT.</p><p><strong>Results: </strong>The cumulative incidence of treatment-induced pneumonitis was 4.6% and occurred in 11/286 patients. Three months incidence rate was 2.6%. Most of the patients diagnosed with treatment-induced pneumonitis had received BEAC as HDT regimen. The risk of treatment-induced pneumonitis was higher if HDT-ASCT was given in later treatment lines. Also, a prior thoracic radiotherapy as part of first-line treatment was associated with higher risk for pneumonitis after HDT-ASCT. In 2 patients, the pneumonitis did not respond to high-dose steroid treatment.</p><p><strong>Conclusion: </strong>This study provides new information about the incidence of pneumonitis associated with HDT-ASCT and its risk factors, which might be useful to take into consideration during and after treatment with HDT-ASCT.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.1,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 pandemic on progression free survival estimates in oncology: the role of non-informative censoring.","authors":"Vadim Lesan, Cristian Munteanu","doi":"10.1159/000551333","DOIUrl":"https://doi.org/10.1159/000551333","url":null,"abstract":"","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.1,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147347080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Integrative Medicine in the Management of Lymphoma Survivors: An Exploratory Preference-Based Controlled Trial.","authors":"Ilana Levy Yurkovski, Samuel Attias, Elad Schiff, Ohad Cohen-Naznin, Esther Anahory, Yael Gross-Geva, Anat Oved, Niki Bleiweiss, Sharon Caspi-Biran, Sally Awad, Tamar Tadmor","doi":"10.1159/000551325","DOIUrl":"10.1159/000551325","url":null,"abstract":"<p><strong>Introduction: </strong>Lymphoma has recovery rates above 60%, but many survivors experience impaired quality-of-life (QoL) requiring survivorship care. This study evaluated the role of an integrative oncology (IO) clinic in managing lymphoma survivors.</p><p><strong>Methods: </strong>In this exploratory preference-based controlled trial, adults in remission after lymphoma treatment were allocated to two groups: those attending the IO survivorship clinic (intervention) and those declining (control). The intervention included complementary medicine, spiritual, and social support, delivered weekly for up to 6 months in addition to standard follow-up. The primary outcome was QoL improvement (EQ-5D-5L index). Secondary outcomes included symptom relief (MYCAW), cognitive function, and perceived control.</p><p><strong>Results: </strong>Twenty-nine patients were enrolled: 15 in the intervention and 14 in the control group. Over the first 3 months, a significant time × group interaction in EQ-5D-5L scores favored the intervention (p = 0.005), reflecting superior QoL trajectory. MYCAW concerns also improved significantly in the intervention group across 6 months (p = 0.005 and p = 0.03). At 3 months, FACT Cog-Oth scores were significantly higher in the intervention arm (p = 0.01), indicating better \"other\" cognitive functions (e.g., memory, clarity, confusion). To note, adherence to IO mainly decreased after 3 months.</p><p><strong>Conclusion: </strong>In this exploratory preference-based study, an IO survivorship clinic for lymphoma survivors was associated with improvements in QoL, especially for adherent patients. Given the preference-based design, these findings should be interpreted cautiously and viewed as hypothesis-generating rather than confirmatory. Further studies are warranted to evaluate long-term benefits and sustainability of this approach.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-14"},"PeriodicalIF":1.1,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Comprehensive Characterization of Lip Lymphoma: A Population-Based Study.","authors":"Pierre Loap, Youlia Kirova","doi":"10.1159/000551039","DOIUrl":"10.1159/000551039","url":null,"abstract":"<p><strong>Introduction: </strong>Lip lymphoma is an exceptionally rare extranodal lymphoma with limited data to guide clinical management. We conducted the first large-scale population-based analysis to characterize its epidemiology, treatment patterns, and outcomes.</p><p><strong>Methods: </strong>We identified all lip lymphoma cases (2000-2022) from the SEER database (17 registries). Patients were categorized as localized primary lip lymphoma (stage I) or lymphoma involving the lip area (stages II-IV).</p><p><strong>Results: </strong>Among 82 patients (median age 62 years, 54.9% female), age-adjusted incidence was 0.0459 per million per year. MALT lymphoma predominated (46.3%). With the median follow-up of 74.5 months, 21 deaths (25.6%) occurred, only 5 (6.1%) lymphoma related. Ten-year overall and cancer-specific survival rates were 72.7% and 92.6%, respectively. In multivariate analysis, age (HR 1.115/year, p < 0.001) and non-low-grade histology (HR 3.251, p = 0.043) independently predicted survival. All lymphoma-related deaths occurred in patients with aggressive or unknown histologies, none in confirmed low-grade B-cell lymphomas. No treatment strategy (surgery, radiotherapy, or systemic treatment) showed a significant superiority in terms of survival.</p><p><strong>Conclusion: </strong>Lip lymphoma demonstrates excellent prognosis, particularly for low-grade B-cell histologies. Age and histological grade represent principal prognostic factors guiding treatment strategies.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.1,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13043128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146211908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of Circular RNAs in Mantle Cell Lymphoma: A Competing Endogenous RNA Network Analysis.","authors":"Chen-Xuan Huang, Xu-Dong Ma, Wei Zhuang, Yong Zou","doi":"10.1159/000547908","DOIUrl":"10.1159/000547908","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the prognostic role of circular RNAs (circRNAs) in individuals diagnosed with mantle cell lymphoma (MCL), using the framework of the competing endogenous RNA (ceRNA) network model.</p><p><strong>Methods: </strong>Differentially expressed circRNAs were identified from the GSE159808 dataset, and differentially expressed messenger RNAs (mRNAs) were extracted from GSE32018. Corresponding microRNAs (miRNAs) were retrieved to construct a ceRNA regulatory network relevant to MCL. Functional enrichment analysis and survival analysis were performed on 35 mRNAs incorporated in the ceRNA network to identify transcripts associated with survival outcomes in MCL. A prognostically relevant ceRNA subnetwork was then constructed based on these results.</p><p><strong>Results: </strong>Thirteen circRNAs (9 upregulated, 4 downregulated) and 457 differentially expressed mRNAs were identified. The initial ceRNA network included 11 circRNAs, 40 miRNAs, and 35 mRNAs. Gene Ontology analysis indicated enrichment in pathways related to dentin-containing tooth development, the plasma membrane signaling receptor complex, and growth factor receptor binding. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis demonstrated significant involvement in the B-cell receptor signaling pathway, Fc gamma (Fcγ) receptor-mediated phagocytosis, and the Wnt signaling pathway. Survival analysis identified six mRNAs significantly associated with overall survival in individuals with MCL. These results were used to derive a refined prognostic ceRNA network consisting of 6 mRNAs, 7 miRNAs, and 6 circRNAs.</p><p><strong>Conclusion: </strong>CircRNAs may regulate MCL prognosis by modulating miRNA-mRNA interactions within the ceRNA network. These findings suggest a regulatory mechanism by which circRNAs contribute to molecular pathways influencing disease progression and survival in MCL.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-15"},"PeriodicalIF":1.1,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146091888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gastro-Intestinal Microbiota in Haematology.","authors":"José Manuel Moreno-Mirón, Guillermo José Ruiz-Argüelles, Moisés Manuel Gallardo-Pérez, Alexa Moreno-Mirón, Ana Paola Rivera-Aguilar, Robert Peter Gale","doi":"10.1159/000550689","DOIUrl":"10.1159/000550689","url":null,"abstract":"<p><strong>Background: </strong>The gastro-intestinal microbiota is a key regulator of systemic immunity and inflammatory tone and it contributes to normal haematopoiesis through microbial metabolites, barrier integrity, and host-microbe immune signalling. Disruption of this has been increasingly linked to the development, clinical course, and treatment-related complications of haematological disorders, including clonal haematopoiesis of indeterminate potential (CHIP), leukaemias, and plasma cell neoplasms (PCNs).</p><p><strong>Summary: </strong>This review synthesises current evidence on how gut microbiota composition and function intersect with haematopoietic regulation and haematological disease biology. We summarise proposed mechanisms - including microbe-derived metabolites (e.g., short-chain fatty acids), pattern-recognition receptor signalling, intestinal permeability, and cytokine-mediated inflammation - that may influence haematopoietic stem and progenitor cell behaviour and immune cell differentiation. We then discuss disease-specific associations of dysbiosis with CHIP, leukaemias, and PCN, as well as the impact of common haematology interventions (antibiotics, chemotherapy, immunomodulatory therapies, and transplantation) on microbial ecology and downstream clinical outcomes. Finally, we highlight methodological challenges and outline priorities for longitudinal, mechanistic, and multi-omics studies to enable microbiota-informed risk stratification and therapeutic modulation.</p><p><strong>Key messages: </strong>(1) The gut microbiota influences haematopoiesis via immune signalling, microbial metabolites, and maintenance of mucosal barrier function. (2) Dysbiosis is associated with CHIP, leukaemias, and PCN, and may contribute through chronic inflammation and altered immune homeostasis. (3) Haematological therapies frequently reshape the microbiota; these changes may affect infection risk, treatment tolerance, and outcomes. (4) Current evidence is largely associative; rigorously designed longitudinal and interventional studies are needed to establish causality and guide clinical translation.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":1.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Prognostic Scoring System, Revised International Prognostic Scoring System, and Molecular International Prognostic Scoring System Had No Identical Prognostic Power Depending on Treatment in Myelodysplastic Syndromes.","authors":"Ghada Abichou, Michael Loschi, Rinzine Sammut, Bochra Sedaki, Sami Benachour, Caroline Fileni, Corinne Ferrero-Vacher, Neila De Pooter, Joy Mouanes-Abelin, Berengere Dadone-Montaudie, Thomas Cluzeau","doi":"10.1159/000549858","DOIUrl":"10.1159/000549858","url":null,"abstract":"<p><strong>Introduction: </strong>The Revised International Prognostic Scoring System (IPSS-R) has long been the standard prognostic tool in the management of myelodysplastic syndromes (MDS). Recently, a new clinical-molecular prognostic model, the IPSS-M, was introduced. This model integrates MDS-related gene mutations and offers improved accuracy and precision in predicting patient outcomes and survival. In this study, we compare the prognostic value and predictive capacity of these prognostic scores across different treatment groups.</p><p><strong>Methods: </strong>IPSS, IPSS-R, and IPSS-M scores were calculated at diagnosis for all eligible MDS patients in this cohort. Sankey diagrams were generated to visually compare the risk stratification across the three scoring systems.</p><p><strong>Results: </strong>A total of 394 patients were included in this retrospective analysis. During the course of the disease, 59.1% required treatment, with 38.1% (150 patients) receiving erythropoiesis-stimulating agents (ESA) and 19.0% (75 patients) treated with hypomethylating agents (HMA). The IPSS-M was calculated for 281 patients and reclassified 41.9% of cases: 20.3% (n = 57) were upstaged and 21.7% (n = 61) were downstaged. All three scoring systems demonstrated significant stratification of overall survival (OS) in the global cohort (p < 0.001 for IPSS, IPSS-R, and IPSS-M). Notably, IPSS failed to predict OS in patients treated with azacitidine, and none of the scores successfully predicted OS in patients treated with ESA.</p><p><strong>Conclusion: </strong>The IPSS-M effectively reclassified 41.9% of patients, upstaging 20.2% and downstaging 21.7%. However, our analysis found that none of the prognostic scores effectively predicted outcomes for ESA-treated patients. Further studies are needed to assess whether the predictive value of these scoring systems is influenced by the specific treatment modalities used.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":1.1,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Graft-versus-Host Disease: A Review of Current Treatments beyond Second-Line and Emerging Therapies.","authors":"Aseel Saadeh, Dayana Jibrin, Michael Haddadin","doi":"10.1159/000550265","DOIUrl":"10.1159/000550265","url":null,"abstract":"<p><strong>Background: </strong>Chronic graft-versus-host disease (cGVHD) remains a major cause of late morbidity and non-relapse mortality following allogeneic hematopoietic cell transplantation. Early identification and intervention are critical to improving outcomes. Corticosteroids continue to serve as the first-line therapy; however, treatment-refractory cases are common and associated with poor outcomes. Ruxolitinib has become the standard second-line agent, yet beyond ruxolitinib, treatment selection varies widely due to a lack of comparative data and standardized sequencing strategies. A comprehensive review of key therapeutic trials in chronic GVHD was conducted, with a focus on second-line treatments and beyond. Emerging and investigational therapies were also included through analysis of recent literature and ongoing studies.</p><p><strong>Summary: </strong>There is currently no established sequencing of agents beyond second-line therapies. The approval of belumosudil, axatilimab, and ibrutinib has expanded therapeutic options, with each agent offering a unique mechanism of action and demonstrating promising organ-specific response rates.</p><p><strong>Key messages: </strong>The therapeutic landscape for chronic GVHD is evolving, with several newer agents beginning to demonstrate utility in third-line settings. However, the selection of third-line agents remains largely dependent on clinical judgment, prior treatment history, and the specific organs involved. There is a continuing and critical need for well-designed, comparative trials to establish optimal treatment strategies.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-10"},"PeriodicalIF":1.1,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}